Oncology Times reports essential clinical news for oncologists, hematologists and other cancer care professionals. Learn more about our award-winning journal!
…
continue reading
In collaboration with Audio Journal of Oncology, OT now features audio-reports and interviews about new clinical research from major cancer meetings and key journals. The programs are created by the leading medical audioservice worldwide, Audio Medica, whose Audio Journal of Oncology has been bringing these lively listen-in shows to members of the cancer care team in various audio formats since 1992. Scientific Editors are: George Canellos, MD, of Dana-Farber Cancer Institute; J. Gordon McVi ...
…
continue reading
1
Mesh-Supported Prepectoral Method of Breast Reconstruction After Breast Cancer Surgery
10:27
10:27
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
10:27
Higher rates of satisfaction and psychosocial well-being and low complication rates were reported by patients who had a new mesh-supported prepectoral method of breast reconstruction using titanized mesh pockets after their surgery for breast cancer. At the 14th European Breast Cancer Conference in Milan, Stefan Paepke, MD, from the Interdisciplina…
…
continue reading
1
Radiotherapy Boost Protects Young Patients With Early Breast Cancer, High Dose Boost Not Needed
8:38
The value of adding a radiation boost to postoperative radiotherapy for patients younger than 50 with early breast cancer has been confirmed by 10 years of data from the Young Boost trial conducted in the Netherlands. However, by randomizing patients between the standard radiation boost and a lower dose boost, the study demonstrated comparable effi…
…
continue reading
1
Breast-Conserving Therapy Effective for Ductal Carcinoma in Situ, But Questions Remain
15:40
15:40
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
15:40
A 30-year-long population-based study, reported at the 14th European Breast Cancer conference held in Milan, Italy, showed that breast-conserving therapy for ductal carcinoma in situ (DCIS) had become increasingly effective in preventing the emergence of breast cancer over the long term, but that there were still unanswered questions. The populatio…
…
continue reading
Most patients whose breast cancer has spread to more than three lymph nodes can nevertheless be spared extensive axillary dissection, according to the findings of a study presented at the 2024 European Breast Cancer Conference in Amsterdam, The Netherlands. Annemiek van Hemert, a Medical Doctor and PhD candidate at the Surgical Oncology Department …
…
continue reading
1
Artificial Intelligence Tool Predicts Postoperative Radiotherapy Lymphedema
34:36
34:36
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
34:36
Artificial intelligence is being harnessed by a team of researchers at Leicester University in the United Kingdom to predict the risk of lymphedema (and potentially other toxicities) from the use of postoperative radiation therapy for breast cancer. The 2024 European Breast Cancer Conference heard the latest news on an artificial intelligence tool …
…
continue reading
New data from the Phase III KEYNOTE-756 clinical trial show that adding pembrolizumab immunotherapy to chemotherapy before and after surgery for high-risk breast cancer (which was estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative) resulted in better outcomes for patients regardless of their age or menopaus…
…
continue reading
Offering MRI-guided partial breast irradiation before surgery to patients with low-risk breast cancer could become the norm, according to Yasmin Civil, MD, in the Department of Radiation Oncology at the Amsterdam UMC in the Netherlands, who reported 5-year results from the ABLATIVE trial to the 14th European Breast Cancer Conference. The researcher…
…
continue reading
Adding checkpoint inhibition immunotherapy to adjuvant chemotherapy did not improve survival among patients with triple-negative breast cancers. These findings from a study reported at the 14th European Breast Cancer Conference were presented by Heather McArthur, MD, MPH, Clinical Director of Breast Cancer and Komen Distinguished Chair in Clinical …
…
continue reading
1
Gene Test Shows Which Triple-Negative Breast Cancers Do Not Need Pre-Op Pembrolizumab
15:44
15:44
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
15:44
About a quarter of all patients with newly diagnosed triple-negative breast cancer will not benefit from neoadjuvant checkpoint inhibitor immunotherapy with an agent such as pembrolizumab—even though it improves outcomes among the remaining majority. At the 14th European Breast Cancer Conference, held in Milan, Italy, Laura van ’t Veer, PhD, Progra…
…
continue reading
1
Triple Therapy for Patients With Mutated FLT3 Gene in Acute Myeloid Leukemia
20:15
20:15
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
20:15
An early study of patients (Phase I/II) with acute myeloid leukemia found that a new three-drug combination therapy greatly improved outcomes—both in patients with relapsed or refractory disease and as initial therapy. The new research involved adding quizartinib that targets fms-related tyrosine kinase 3 (FLT3) oncogene. Mutations of FLT3 are pres…
…
continue reading
1
Important Mantle Cell Lymphoma Findings From the Sympatico Study
13:55
13:55
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
13:55
How best to treat patients with relapsed or refractory mantle cell lymphoma has been made clearer by a report from the multinational Phase III Sympatico Study, presented at the 65th ASH Annual Meeting and Exposition held in San Diego. Lead author Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at the University of Texas MD Ander…
…
continue reading
1
World’s Largest Prostate Cancer Trial, STAMPEDE, Celebrates 20 Years of Progress
17:44
17:44
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
17:44
2024 is the 20th year of clinical studies conducted as part of the STAMPEDE (Systemic Therapy in Advancing or Metastatic Prostate Cancer: Evaluation of Drug Efficacy) trial, a series of investigational approaches to initial therapy for patients with high-risk prostate cancer. Patient accrual has now ended, but practice-changing data continue to eme…
…
continue reading
1
Doublet Inhibitor Therapy Restrains Metastatic EGFR-Mutated NSCLC Progression
16:00
16:00
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
16:00
The multicenter RAMOSE randomized clinical trial has found that doublet growth factor tyrosine kinase inhibitor therapy, when compared with standard osimertinib monotherapy, achieved a statistically significant improvement in progression-free survival in patients whose advanced non-small cell lung cancers were driven by mutated epidermal growth fac…
…
continue reading
1
Gene-Targeted Agent Brings Clinical Benefit in R/R Acute Leukemias
24:23
24:23
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
24:23
A new targeted drug, revumenib, was found to increase response rates and survival in patients whose previously treated acute leukemias relapsed or were refractory to treatment. A Phase II clinical study found revumenib met its primary endpoint and was stopped early because of a high patient response rate and clinical efficacy. Revumenib acts on the…
…
continue reading
1
INTERLACE Study Boosts Cervical Cancer Survival
18:14
18:14
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
18:14
A marked improvement in the outlook for patients with locally advanced cervical cancer has been achieved thanks to a neoadjuvant regimen using standard anti-cancer drugs added to usual therapy. At the ESMO Congress 2023 held in Madrid, Spain, Mary McCormack, PhD, MBBS, FRCR, Consultant Clinical Oncologist at University College London Hospitals, rep…
…
continue reading
1
RET Fusion-Targeted Drug Doubles Progression-Free Survival in NSCLC Patients
18:43
18:43
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
18:43
Patients whose advanced non-small cell lung cancers harbor the RET gene fusion should receive initial treatment with the RET-targeted agent selpercatinib rather than chemotherapy or chemotherapy combined with immunotherapy. This clear message comes from the randomized Phase III LIBRETTO-431 study reported at ESMO Congress 2023 by Herbert Ho Fung Lo…
…
continue reading
The preferred first-line treatment for patients with uncommon sensitizing mutations in tumor epidermal growth factor receptor (EGFR) should now be the tyrosine kinase inhibitor (TKI) afatinib, rather than osimertinib, according to Japanese researchers reporting the ACHILLES trial results at the ESMO Congress 2023 held in Madrid. OncTimesTalk corres…
…
continue reading
1
Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
15:24
15:24
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
15:24
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the ESMO Congress 2023. These results support the use of early salvage radiotherapy…
…
continue reading
1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors Into “Hot” Ones
14:51
14:51
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
14:51
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin-12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it couldn’t be used because of toxicity. At t…
…
continue reading
1
Allogeneic Transplant for AML: Only in Patients Negative for Molecular Minimum Residual Disease
15:43
15:43
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
15:43
The process of identifying which patients with acute myeloid leukemia (AML) can benefit from allogeneic stem cell transplantation in first complete remission (CR1) has taken a step forward thanks to analysis of the UK NCRI AML17 and AML19 studies, reported at the 65th ASH Annual Meeting and Exposition. Patients who achieved molecular residual disea…
…
continue reading
1
Antibody-Drug Conjugate Brings Success in High-Risk R/R Follicular Lymphoma
22:11
22:11
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
22:11
With no standard-of-care treatment for patients with high-risk relapsed/refractory follicular lymphoma, promising remissions have been observed in a Phase II study reported at the 65th ASH Annual Meeting and Exposition. The antibody-drug conjugate loncastuximab tesirine in combination with rituximab brought a very high complete metabolic response r…
…
continue reading
1
Pirtobrutinib After Covalent BTK Inhibitor - Double Refractory CLL
12:16
12:16
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
12:16
Patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) have poor outcomes after the failure of covalent Bruton's tyrosine kinase (BTK) inhibitor treatment, and new therapeutic options are needed. Pirtobrutinib, a highly selective, noncovalent (reversible) BTK inhibitor, was designed to re-establish BTK inhibition.…
…
continue reading
1
Relapsed or Refractory CLL - With Sameer A. Parikh, MBBS, and Alessandra Ferrajoli, MD
12:32
12:32
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
12:32
In a multinational, Phase III, head-to-head trial, ibrutinib, a Bruton's tyrosine kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater specificity, as treatment for relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). In prespecified interim analyses, zanubrutinib was superio…
…
continue reading
1
CLL Frontline Treatment - With Sameer A. Parikh, MBBS, & Alessandra Ferrajoli, MD
14:40
14:40
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
14:40
Randomized trials of venetoclax plus anti-CD20 antibodies as first-line treatment in fit patients (i.e., those with a low burden of coexisting conditions) with advanced chronic lymphocytic leukemia (CLL) have been lacking.
…
continue reading
1
Sabestomig in Non-Small Cell Lung Cancer: Bi-Specific Antibody Safe and Active
11:10
11:10
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
11:10
Patients with non-small cell lung cancer who have failed initial immunotherapy therapy with anti-programmed cell death ligand-1 (PDL-1) checkpoint inhibitors, have responded to a new “bispecific” antibody that targets both the programmed cell death-1 (PD-1) antibody and also the T-cell immunoglobulin and mucin domain 3 (TIM-3) molecule. Benjamin Be…
…
continue reading
1
Radicals Study Finds Adjuvant Radiotherapy No Benefit After Radical Prostatectomy
15:23
15:23
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
15:23
Patients with high-risk prostate cancer who have been treated with radical prostatectomy gain no additional advantage and face extra toxicity if they choose to have adjuvant radiotherapy. That’s according to the findings of the randomized RADICALS study, reported at the 2023 annual congress of the European Society for Medical Oncology (ESMO) held i…
…
continue reading
1
Two Drug Combination Benefits Patients with nRAS-Mutated Melanoma Refractory to Checkpoint Inhibition
13:38
13:38
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
13:38
Research presented at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics found that a combination of two drugs targeting the nRAS mutation had clinical activity in patients with checkpoint-inhibitor refractory melanoma and had potential for treating other solid tumors with mutated nRAS as their oncogenic d…
…
continue reading
1
Collagen-Bound Interleukin 12 Converts “Cold” Tumors into “Hot” Ones
14:50
14:50
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
14:50
Although immunotherapies for patients with solid tumors such as melanoma can be dramatically successful, the majority of patients are resistant and require alternative treatments. While the cytokine interleukin 12 is well known for potentiating the effect of immunotherapies, such as checkpoint blockade, it could not be used because of toxicity. At …
…
continue reading
1
Double TKI Therapy Improves Responses in MET Amplification-Driven EGFR-Mutant Non-Small Cell Lung Cancer
15:22
15:22
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
15:22
Among patients with non-small cell lung cancers driven by mutations in the epidermal growth factor receptor (EGFR), those with MET-amplification can now be selected for therapy with two tyrosine kinase inhibitor drugs, not just standard osimertinib. That’s according to conclusions from the INSIGHT 2 study reported at the AACR-NCI-EORTC internationa…
…
continue reading
1
CLIC Protein Inhibition Key to Metformin’s Anti-Neoplastic Properties
24:17
24:17
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
24:17
The Chloride Intracellular Channel 1 (CLIC1) protein appears to hold the key to understanding the anti-proliferative action of metformin, according to laboratory evidence discussed at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics held in October 2023, in Boston. At the conference, Michele M. Mazzanti, PhD,…
…
continue reading
1
Adjuvant ATR Inhibition Prolonged Life in Patients with Relapsed Small Cell Lung Cancer
18:59
18:59
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
18:59
Dr. Takahashi talks with OncTimes Talk’s Peter Goodwin about the Phase 2 study he presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 11 - 15, 2023. Dr. Takahashi reported an improvement in median overall survival among patients with relapsed small cell lung cancer who had the ATR inhibitor…
…
continue reading
1
Mitophagy Discovered as Potential Reason for AML’s Resistance to Venetoclax
15:20
15:20
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
15:20
Acute myeloid leukemia (AML) is notoriously difficult to treat. Only 28 percent of patients survive beyond 5 years after diagnosis. Mitophagy, a process in which damaged mitochondria are eliminated to prevent the transmission of death signals, has been identified as a key mechanism that allows leukemia cells to resist the effects of the widely pres…
…
continue reading
1
Unintentional Bias of Breast Cancer Randomized Clinical Trial Interpretations Through Discontinuation Imbalance
11:54
11:54
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
11:54
Some of the big randomized clinical trials could lead to unintentional bias because of an imbalance of assigned treatment discontinuations between experimental and control arms, according to ASCO poster author Faris Tamimi, MD, at the University Health Network Division of Medical Oncology and Hematology at Princess Margaret Cancer Centre. OncTimesT…
…
continue reading
1
Trastuzumab Deruxtecan Benefits Patients with HER2-Low Metastatic Breast Cancer Irrespective of ER Expression
11:43
11:43
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
11:43
Although T-DXd had already been licensed for use in all categories of HER2 positivity, including patients with so-called HER2-low tumors (defined as having immunohistochemical score of 1+ or 2+ with non-amplified in-situ hybridization), doubts have remained about the effectiveness of this antibody drug conjugate in the subset of such patients who a…
…
continue reading
1
Artificial Intelligence Model Predicts Overall Survival in Patients with Metastatic Breast Cancer
9:17
A mathematical study of real-world data from 27,855 women whose breast cancer was diagnosed between 2008 and 2020 has shown that a machine-learning artificial intelligence algorithm was able to predict mortality and could become a key weapon in the clinician’s armory when selecting therapies on the basis of predicted survival. Initial findings and …
…
continue reading
Caution was expressed at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting about potential adverse effects from one form of breast cancer treatment de-escalation. A poster warns about risks from omitting axillary sentinel node surgery in older women. In this edition of OncTimesTalk correspondent Peter Goodwin hears about axillary…
…
continue reading
1
Variability of Biological Parameters Between Tumor Biopsy & Surgical Samples in Breast Cancer Patients
8:16
A real-world study reported at the ESMO Breast Cancer 2023 Annual Congress identified a risk for inappropriate therapeutic decision-making resulting from an alarmingly high rate of false-negative tests coming from biopsy specimens looking for biological parameters such as PR and HER2. Study researchers at the University of Catania suggested tumor h…
…
continue reading
1
Full Compliance With Adjuvant Endocrine Therapy Brings 15 Percent Superior Survival in Patients With Breast Cancer
3:42
Patients with breast cancer who complied fully with their adjuvant endocrine medication lived 15 percent longer than those who skipped doses, according to a huge real-world study coordinated from Tübingen University, in Baden-Württemberg, Germany, reported at the 2023 ASCO Annual Meeting. OncTimesTalk correspondent Peter Goodwin discusses the findi…
…
continue reading
1
Being Obese & Overweight Reduces Efficacy of Extended Endocrine Therapy in HR+ Breast Cancer
14:17
14:17
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
14:17
Being overweight or obese can reduce the benefit of extending adjuvant breast cancer hormone therapy in women younger than 60 years, according to research from the DATA trial discussed at the European Society for Medical Oncology (ESMO) Breast Cancer 2023 Congress. Senna W.M. Lammers, MD, from Maastricht University Medical Centre in The Netherlands…
…
continue reading
1
ASCO 2023: Neoadjuvant Pembrolizumab Brought Big Benefit in Early-Stage Non-Small Cell Lung Cancer with Heather A. Wakelee, MD, FASCO
11:05
11:05
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
11:05
Non-small cell lung cancer was one of the big topics at the 2023 ASCO Annual Meeting where Heather Wakelee, MD, FASCO, Professor of Medicine and Chief of the Division of Oncology at Stanford University in California, was overheard reminding a junior cancer doctor that the only adjuvant therapy for lung cancer had been chemotherapy just a couple of …
…
continue reading
1
ASCO 2023: How AI Can Help Physicians Communicate with Dying Patients Better & Also Reduce Costs
7:14
End-of-life care for patients with cancer could be significantly improved while simultaneously reducing cost according to the findings of a study from the University of Pennsylvania. Ravi Parikh, MD, MPH, talks with OncTimesTalk correspondent Peter Goodwin about his findings on the value of harnessing AI to help doctors have serious illness convers…
…
continue reading
Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…
…
continue reading
1
Targeted Adjuvant Therapy in Non-Small Cell Lung Cancer with Roy Herbst, MD PhD
11:04
11:04
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
11:04
Roy Herbst, MD PhD, Deputy Director of the Yale Cancer Center at Yale School of Medicine, talks with OncTimesTalk correspondent Peter Goodwin about his group’s findings from the international Phase III ADAURA clinical trial looking at adjuvant therapy with the anti EGFR-mutant drug osimertinib in patients with completely resected stage one B to thr…
…
continue reading
1
Emerging Cancer Treatments for Esophageal Cancer with Brian Henick, MD
24:46
24:46
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
24:46
Progress in esophageal cancer is forging ahead at Columbia University in New York. Brian Henick, MD, is a medical oncologist specializing in the care of patients with malignancies of the aerodigestive tract. As Associate Director of Experimental Therapeutics and Director of Translational Research in Aerodigestive Cancers in Medical Oncology, Henick…
…
continue reading
1
Meet the New Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP
15:05
15:05
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
15:05
Today we are introducing the new Oncology Times Editorial Board Chair: Stephanie L. Graff, MD, FACP. In her new role, Graff will help Oncology Times continue to provide essential clinical news and analysis for the cancer care community.Graff is Director of Breast Oncology at Lifespan Cancer Institute and Assistant Professor of Medicine at Brown Uni…
…
continue reading
1
Ravi B. Parikh, MD, on How Machine Learning-Triggered Reminders Can Improve End-of-Life Care for Cancer Patients
21:05
21:05
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
21:05
When cancer advances to an incurable stage, some patients may prioritize treatment that will extend their life as long as possible, and others may prefer a care plan that’s designed to minimize pain. Talking to patients about their prognosis and values can help clinicians develop care plans that are better aligned to each patient’s goals. However, …
…
continue reading
1
Deanna Gerber, MD, on Navigating Cervical Cancer Screening
13:02
13:02
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
13:02
Despite increased screening and HPV vaccines, cervical cancer remains the fourth-leading cause of cancer death among women worldwide. Screening guidelines are constantly scrutinized and reassessed. The most current U.S. Preventative Services Task Force (USPSTF) guidelines recommend screening for cervical cancer every 3 years with cervical cytology …
…
continue reading
1
January Research Review: Promising Results in HemOnc Clinical Trials
43:58
43:58
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
43:58
This episode is Research Review, a quarterly review of the research you may have missed. Today, we are covering the American Society of Hematology Annual Meeting highlights. First Up, results from the ECOG-ACRIN E1910 Randomized Phase III clinical trial showed that blinatumomab improved overall survival in newly diagnosed adult patients with b-line…
…
continue reading
1
Unraveling a Complex Disease: Gary K. Schwartz, MD, on Sarcoma Research Highlights, Targeted Agents & Future Directions
30:06
30:06
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
30:06
Sarcoma represents an incredibly rare group of cancers comprised of 50 histologic subtypes, with approximately 13,000 new diagnoses per year. Each histologic type exhibits a unique biologic behavior, and, as such, prognosis and optimal treatment strategies vary. Sarcoma can appear anywhere in the body, and local invasion of nearby organs may make s…
…
continue reading
1
ASH 2022: David Sallman, MD, Discusses Positive Phase I Dose Escalation Data for PRGN-3006 UltraCAR-T in AML Patients
17:52
17:52
Later Afspelen
Later Afspelen
Lijsten
Vind ik leuk
Leuk
17:52
A study using chimeric antigen receptor (CAR)-T cells has proven to be safe for treating patients with relapsed or refractory acute myeloid leukemia (AML). The agent known as PRGN-3006 also brought remissions among patients who had chemotherapy for lymphodepletion prior to their CAR-T cell procedure (Abstract 4633). After the lead author of the new…
…
continue reading